Age-related changes in 11β-hydroxysteroid dehydrogenase type 2 activity in normotensive subjects

American Journal of Hypertension

Volumn 26, Issue 4, 2013, Pages 481-487

  Campino, Carmen ^a,b   Martinez Aguayo, Alejandro ^b   Baudrand, Rene ^a,b   Carvajal, Cristian A ^a,b   Aglony, Marlene ^b   Garcia, Hernan ^b   Padilla, Oslando ^a   Kalergis, Alexis M ^b   Fardella, Carlos E ^a,b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

11 HSD2 activity; age; blood pressure; essential hypertension; hypertension

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; CORTISONE; HYDROCORTISONE;

ADULT; AGING; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME ACTIVITY; FEMALE; GROUPS BY AGE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; PLASMA RENIN ACTIVITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ADOLESCENT; ADULT; AGING; BLOOD PRESSURE; CHILD; CORTISONE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROCORTISONE; HYPERTENSION; MALE; MIDDLE AGED; RENIN;

EID: 84876540772     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hps080     Document Type: Article

References (33)

1. Schmieder RE, Messerli FH, Ruddel H. Risks for arterial hypertension. Cardiol Clin 1986; 4:57-66. (Pubitemid 16087734)
2. Luft FC, Weinberger MH, Fineberg NS, Miller JZ, Grim CE. Effects of age on renal sodium homeostasis and its relevance to sodium sensitivity. Am J Med 1987; 82:9-15.
3. Alikhani-Koupaei R, Fouladkou F, Fustier P, Cenni B, Sharma AM, Deter HC, Frey BM, Frey FJ. Identification of polymorphisms in the human 11beta-hydroxysteroid dehydrogenase type 2 gene promoter: functional characterization and relevance for salt sensitivity. FASEB J 2007; 21:3618-3628. (Pubitemid 350075151)
4. Lovati E, Ferrari P, Dick B, Jostarndt K, Frey BM, Frey FJ, Schorr U, Sharma AM. Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab 1999; 84:3745-3749. (Pubitemid 30645235)
5. Campino C, Carvajal CA, Cornejo J, San Martin B, Olivieri O, Guidi G, Faccini G, Pasini F, Sateler J, Baudrand R, Mosso L, Owen GI, Kalergis AM, Padilla O, Fardella CE. 11beta-Hydroxysteroid dehydrogenase type-2 and type-1 (11beta-HSD2 and 11beta-HSD1) and 5beta-reductase activities in the pathogenia of essential hypertension. Endocrine 2010; 37:106-114.
6. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994; 105:R11-R17.
7. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987; 237:268-275. (Pubitemid 17095145)
8. Ferrari P, Lovati E, Frey FJ. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. J Hypertens 2000; 18:241-248. (Pubitemid 30142838)
9. Krug AW, Allenhofer L, Monticone R, Spinetti G, Gekle M, Wang M, Lakatta EG. Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways. Hypertension 2010; 55:1476-1483.
10. Carvajal CA, Gonzalez AA, Romero DG, Gonzalez A, Mosso LM, Lagos ET, Hevia Mdel P, Rosati MP, Perez-Acle TO, Gomez-Sanchez CE, Montero JA, Fardella CE. Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab 2003; 88:2501-2507. (Pubitemid 36724415)
11. Rodriguez JA. [Syndrome of apparent mineralocorticoid excess caused by a deficiency of 11 beta-hydroxysteroid dehydrogenase: clinical and genetic study in a Chilean family followed for 19 years]. Rev Med Chil 2000; 128:17-26.
12. Heilmann P, Heide J, Hundertmark S, Schoneshofer M. Administration of glycyrrhetinic acid: significant correlation between serum levels and the cortisol/cortisone-ratio in serum and urine. Exp Clin Endocrinol Diabetes 1999; 107:370-378. (Pubitemid 29479093)
13. Arteaga E, Fardella C, Campusano C, Cardenas I, Martinez P. Persistent hypokalemia after successful adrenalectomy in a patient with Cushing's syndrome due to ectopic ACTH secretion: possible role of 11beta-hydroxysteroid dehydrogenase inhibition. J Endocrinol Invest 1999; 22:857-859. (Pubitemid 30083179)
14. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969; 44:291-303.
15. Falkner B, Daniels SR. Summary of the fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Hypertension 2004; 44:387-388. (Pubitemid 39281480)
16. Loureiro C, Campino C, Martinez-Aguayo A, Godoy I, Aglony M, Bancalari R, Garcia H, Carvajal CA, Fardella C. Positive association between aldosterone-renin ratio and carotid intima-media thickness in hypertensive children. Clin Endocrinol (Oxf) 2013; 78(3):352-357.
17. Carvajal CA, Romero DG, Mosso LM, Gonzalez AA, Campino C, Montero J, Fardella CE. Biochemical and genetic characterization of 11 beta-hydroxysteroid dehydrogenase type 2 in low-renin essential hypertensives. J Hypertens 2005; 23:71-77. (Pubitemid 40128983)
18. Stewart PM. Cortisol as a mineralocorticoid in human disease. J Steroid Biochem Mol Biol 1999; 69:403-408. (Pubitemid 29305562)
19. Dotsch J, Hohenberger I, Peter M, Sippell W, Dorr HG. Evidence for change of 11beta-hydroxysteroid dehydrogenase activity during infancy and childhood. Pediatr Res 2000; 48:697-700.
20. Henschkowski J, Stuck AE, Frey BM, Gillmann G, Dick B, Frey FJ, Mohaupt MG. Age-dependent decrease in 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) activity in hypertensive patients. Am J Hypertens 2008; 21:644-649. (Pubitemid 351733361)
21. Morineau G, Boudi A, Barka A, Gourmelen M, Degeilh F, Hardy N, al-Halnak A, Soliman H, Gosling JP, Julien R, Brerault JL, Boudou P, Aubert P, Villette JM, Pruna A, Galons H, Fiet J. Radioimmunoassay of cortisone in serum, urine, and saliva to assess the status of the cortisolcortisone shuttle. Clin Chem 1997; 43:1397-1407. (Pubitemid 27329788)
22. Sharmin S, Guan H, Williams AS, Yang K. Caffeine reduces 11betahydroxysteroid dehydrogenase type 2 expression in human trophoblast cells through the adenosine A(2B) receptor. PLoS One 2012; 7:e38082.
23. Mazzocchi G, Rossi GP, Neri G, Malendowicz LK, Albertin G, Nussdorfer GG. 11beta-hydroxysteroid dehydrogenase expression and activity in the human adrenal cortex. FASEB J 1998; 12:1533-1539. (Pubitemid 28506722)
24. Lienhard D, Lauterburg M, Escher G, Frey FJ, Frey BM. High salt intake down-regulates colonic mineralocorticoid receptors, epithelial sodium channels and 11beta-hydroxysteroid dehydrogenase type 2. PLoS One 2012; 7:e37898.
25. Ma X, Lian QQ, Dong Q, Ge RS. Environmental inhibitors of 11betahydroxysteroid dehydrogenase type 2. Toxicology 2011; 285:83-89.
26. Zhao B, Lian Q, Chu Y, Hardy DO, Li XK, Ge RS. The inhibition of human and rat 11beta-hydroxysteroid dehydrogenase 2 by perfluoroalkylated substances. J Steroid Biochem Mol Biol 2011; 125:143-147.
27. Morris DJ, Latif SA, Hardy MP, Brem AS. Endogenous inhibitors (GALFs) of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol. J Steroid Biochem Mol Biol 2007; 104:161-168. (Pubitemid 46891822)
28. Paulsen SK, Pedersen SB, Jorgensen JO, Fisker S, Christiansen JS, Flyvbjerg A, Richelsen B. Growth hormone (GH) substitution in GH-deficient patients inhibits 11beta-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression in adipose tissue. J Clin Endocrinol Metab 2006; 91:1093-1098. (Pubitemid 43357786)
29. Jensen Pena C, Monk C, Champagne FA. Epigenetic effects of prenatal stress on 11beta-hydroxysteroid dehydrogenase-2 in the placenta and fetal brain. PLoS One 2012; 7:e39791.
30. Wauthier V, Verbeeck RK, Calderon PB. The effect of ageing on cytochrome p450 enzymes: consequences for drug biotransformation in the elderly. Curr Med Chem 2007; 14:745-757. (Pubitemid 46477709)
31. Alikhani-Koopaei R, Fouladkou F, Frey FJ, Frey BM. Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression. J Clin Invest 2004; 114:1146-1157. (Pubitemid 39578704)
32. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994; 7:536-540. (Pubitemid 24308343)
33. Friso S, Pizzolo F, Choi SW, Guarini P, Castagna A, Ravagnani V, Carletto A, Pattini P, Corrocher R, Olivieri O. Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension. Atherosclerosis 2008; 199:323-327.